---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-25-000010"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:46:13.653523+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio reports Phase 2b RA trial success; rosnilimab hits primary endpoint, 69% CDAI LDA at week 14

## Summary
- Phase 2b RENOIR trial (n=424) met primary endpoint (mean DAS-28 CRP change at week 12) across all three doses vs placebo (p<0.01).
- At week 14, 69% of rosnilimab-treated patients achieved CDAI low disease activity, described as highest ever reported.
- Favorable safety: no malignancies, no MACE, no serious infection elevation vs placebo; discontinuations low at 1-2%.
- Full week 28 data expected Q2 2025; top-line week 12 rosnilimab UC data now anticipated in Q4 2025.
- CEO states results exceed target product profile in ~$20B U.S. RA market.

## SEC filing metadata
- accession: 0001370053-25-000010
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000010/0001370053-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000010/anab-20250212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-25-000010
- JSON: https://secwatch.observer/filing/0001370053-25-000010.json
- Plain text: https://secwatch.observer/filing/0001370053-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.